Our finding that IDO1 immunoreactivity was confined to tumor blood vessels (and not in adjacent normal kidney vessels), suggests that RCC tumors are using the well-described immunosuppressive mechanism of intra-tumoral activation of IDO1 expression and enhancement of the local kynurenine pathway [6]. This evidence concerns the gene IDO1 and renal cell adenocarcinoma.